Identifying new ways to inhibit cancer development is of critical import for health research. Prof Hollstein (Leeds) will work with colleagues from Sheffield and York to establish a unique model for examining various aspects of p53 function and cancer development. It will specifically provide a tumour angiogenesis model for assessing anti-angiogenic therapies and analysing changes in DNA-damage response pathways. Given the importance of identifying new anti-cancer therapeutics to global health, access to a strong model system will enable translational collaborations to be formed within the Yorkshire area. This funding will promote strong and sustained collaboration between the involved researchers and will result in research publications and large-scale grant applications.